Skip to main content
. Author manuscript; available in PMC: 2021 Aug 12.
Published in final edited form as: J Med Chem. 2020 Oct 23;63(21):12642–12665. doi: 10.1021/acs.jmedchem.0c00943

Figure 1.

Figure 1.

Overview of direct antiandrogens (1–6), an indirect LBD antagonist (7), and our preclinical SARDs (8–10). Clinically approved agents include first-generation (1–3) and second-generation (4–6) antiandrogens and an indirect androgen synthesis inhibitor (7). Also shown are our SARDs (8–10), which are pan-antagonists in preclinical development for the treatment of antiandrogen-resistant PC.